Ascentage Pharma Group International (AAPG) Non-Current Assets (2023 - 2025)
Ascentage Pharma Group International (AAPG) has disclosed Non-Current Assets for 3 consecutive years, with $143.7 million as the latest value for Q4 2025.
- For Q4 2025, Non-Current Assets fell 9.73% year-over-year to $143.7 million; the TTM value through Dec 2025 reached $143.7 million, down 9.73%, while the annual FY2025 figure was $145.8 million, 6.96% down from the prior year.
- Non-Current Assets hit $143.7 million in Q4 2025 for Ascentage Pharma Group International, down from $159.2 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $160.6 million in Q4 2023 and bottomed at $143.7 million in Q4 2025.
- Average Non-Current Assets over 3 years is $154.5 million, with a median of $159.2 million recorded in 2024.
- Year-over-year, Non-Current Assets decreased 0.85% in 2024 and then decreased 9.73% in 2025.
- Ascentage Pharma Group International's Non-Current Assets stood at $160.6 million in 2023, then decreased by 0.85% to $159.2 million in 2024, then decreased by 9.73% to $143.7 million in 2025.
- According to Business Quant data, Non-Current Assets over the past three periods came in at $143.7 million, $159.2 million, and $160.6 million for Q4 2025, Q4 2024, and Q4 2023 respectively.